Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P42224
UPID:
STAT1_HUMAN
Alternative names:
Transcription factor ISGF-3 components p91/p84
Alternative UPACC:
P42224; A8K989; B2RCA0; D2KFR8; D3DPI7; Q53S88; Q53XW4; Q68D00; Q9UDL5
Background:
Signal transducer and activator of transcription 1-alpha/beta (STAT1) plays a pivotal role in mediating cellular responses to a broad spectrum of cytokines, growth factors, and interferons. Activation of STAT1 is crucial for the antiviral state of cells, driven by its ability to transduce signals and activate transcription of interferon-stimulated genes.
Therapeutic significance:
STAT1 is intricately linked to several immunodeficiencies, including Immunodeficiency 31B, 31A, and 31C, highlighting its critical role in immune system function. Targeting STAT1 pathways offers promising avenues for treating these conditions by enhancing or modulating immune responses.